New drug aims to supercharge immune system against Hard-to-Treat cancers

NCT ID NCT06302426

Recruiting now Disease control Sponsor: Inimmune Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called INI-4001, which is designed to activate the immune system to fight advanced solid tumors. About 50 adults with cancers that have spread or cannot be removed will receive the drug alone or combined with standard immunotherapy drugs like nivolumab or pembrolizumab. The main goal is to find the safest dose and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INI-4001 (a drug that activates the immune system to attack tumors), given alone or with nivolumab or pembrolizumab
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors by boosting the body's immune response.
What could go wrong: This is a very early Phase 1 trial with only 50 people, so it may not work or could have side effects. The main goal is just to find a safe dose, not to prove effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cabrini Hospital
RECRUITING

Malvern, Victoria, 3144, Australia
Southern Oncology Clinical Research Unit
RECRUITING

Bedford Park, South Australia, 5042, Australia
The Border Cancer Hospital
RECRUITING

Albury, New South Wales, 2640, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.